IDRSF (IDRSF) Stock Price & Analysis
IDRSF (IDRSF) rose 0.00% to USD 7.6 as of July 26, 2026 at 08:19 UTC, according to Nexqual real-time market data.
IDRSF last closed at USD 7.6; the session ranged USD 4.4–4.4 on volume of 250 shares. Market capitalization is $1.94B, with a 52-week range of USD 3.3–8 (PNK). Source: Nexqual, July 26, 2026 at 08:19 UTC.
Key Statistics (as of July 26, 2026 at 08:19 UTC)
| Price | USD 7.6 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 7.6 |
| Open | USD 4.4 |
| Day Range | USD 4.4 – 4.4 |
| 52-Week Range | USD 3.3 – 8 |
| Volume | 250 shares |
| Market Cap | $1.94B |
| Exchange | PNK |
Technical Analysis (IDRSF)
Nexqual's technical model rates IDRSF "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 26, 2026 at 08:19 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.41 (neutral) |
| vs SMA50 | Above (USD 6.67) |
| MACD | 0.27 (positive) |
Analyst Ratings (IDRSF)
Wall Street analysts rate IDRSF "None", per Nexqual as of July 26, 2026 at 08:19 UTC.
| Consensus Rating | None |
|---|
Earnings (IDRSF)
| Next Earnings Date | 2026-07-30 |
|---|---|
| Revenue Estimate | $49.00M |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Financials & Fundamentals (IDRSF)
| Total Revenue | $219.10M |
|---|---|
| Revenue Growth (YoY) | -2.50% |
| Gross Margin | +42.93% |
| Operating Margin | -46.22% |
| Profit Margin | -100.65% |
| Current Ratio | 1.6 |
| Total Cash | $94.70M |
| Total Debt | $1.32B |
| Free Cash Flow | $-49.65M |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Financial Health Score (IDRSF)
Nexqual rates IDRSF's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 08:19 UTC.
| Growth | Strong — Revenue +96% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 43%, operating -46% |
| Balance Sheet | Mixed — $95M cash vs $1.32B debt |
| Cash Flow | Weak — FCF negative: -$50M, burning cash |
| Efficiency | Mixed — No data |
Ownership (IDRSF)
| Insider Ownership | +29.59% |
|---|---|
| Institutional Ownership | +26.76% |
| Shares Outstanding | 255.04M |
| Float | 157.87M |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Leadership (IDRSF)
IDRSF is led by Jean-Paul Clozel (age 70), Chairman of the Board & Interim CEO, per Nexqual as of July 26, 2026 at 08:19 UTC.
| Chairman of the Board & Interim CEO | Jean-Paul Clozel (age 70) |
|---|---|
| Executive VP & CFO | Arno Groenewoud (age 54) |
| Executive VP, Chief Scientific Officer & Head of Research | Martine Clozel (age 70) |
| President of Idorsia US | Shalom Jacobovitz (age 64) |
Major Backers & Investors (IDRSF)
Notable institutional backers of IDRSF include Fidelity, according to Nexqual as of July 26, 2026 at 08:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 3.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.72% |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UCBJY | UCB S.A. | USD 139.01 | ▼ 0.04% |
| GNMSF | Genmab A/S | USD 274.5 | ▲ 0% |
| CMXHF | CSL Ltd. | USD 81.96 | ▲ 0% |
| IVBXF | Innovent Biologics Inc. | USD 10.83 | ▼ 15.39% |
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 4.6 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:19 UTC. This page is informational and not investment advice.